Keywords: sb, kytril, oked, new, indication, smithkline, beecham

SB's Kytril OKed for new indication

Article | 03 August 1999

Print This

SmithKline Beecham has been granted a US marketing license for its5-HT3 receptor antagonist Kytril (granisetron HCl) for the prevention ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in